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Abstract 
 
Phytoestrogens, plant produced hormones, are marketed to alleviate menopausal symptoms because 
studies indicate increased incidence of breast cancer in women undergoing estrogen Hormone 
Replacement Therapy. We studied the potential proliferative effects of phytoestrogens on the breast 
cancer cell line T47D-KBluc. HPLC isolated components of black cohosh, red clover, and grape seed 
extracts were assessed for proliferative effects using the MTT assay. Our results suggest that grape seed 
demonstrated the greatest proliferative effects.  
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Background 
Introduction 
Menopause is defined by the permanent cessation of menstruation due to a loss of function in the 
ovaries, which produce eggs as well as the female hormone estrogen. Women going through 
menopause are typically in their forties or fifties and experience symptoms such as hot flashes, night 
sweats, sleep disturbances, and changes in vaginal and urinary tracts. In the past, a standard treatment 
to regulate these uncomfortable symptoms was hormone replacement therapy (HRT) which uses 
synthetic hormones such as estrogen and progesterone to normalize fluctuating hormone levels. Studies 
now show that HRT may have many negative and life-threatening side effects such as breast and ovarian 
cancer (“Menopausal hormone therapy and cancer”, 2011). This resulted in many women turning to 
phytoestrogens as alternatives to combat their menopausal symptoms. Phytoestrogens are 
phytochemicals naturally occurring in plant compounds that can mimic the effects of estrogen and thus 
have the potential to alleviate the symptoms of menopause. While phytoestrogens are part of a daily 
diet available in foods such as soy, red grapes, and legumes, they are marketed to menopausal women 
as dietary supplements that are a safe and natural alternative to estrogen. However, these supplements 
are not regulated as strictly by the Food and Drug Administration (FDA) as substances that are classified 
as drugs; therefore, their side effects are not well understood and may include an increased risk for 
breast cancer.  
 
Part 1: Hormones and Hormone Therapy  
Hormones 
Hormones are the chemical messengers in the human body that control processes such as growth and 
development, metabolism, sexual function, reproduction, and mood.  These chemical messengers are 
stored and released as needed by glands in the endocrine system. The major endocrine glands include 
the pituitary, pineal, thymus, thyroid, and adrenal glands, along with the pancreas, testes in males, and 
ovaries in females. Once the body signals the glands to release the hormones, they travel through the 
blood to reach tissues or organs that contain specific target cells. The hormones bind to the receptor 
molecule of the target cell, which can lead to a change in shape of the receptor and ultimately a cellular 
response. Many organs in the body, specifically reproductive organs and tissues, have estrogen and 
progesterone receptors. Estrogen is particularly important for sexual and reproductive development in 
women. It is mostly produced in the ovaries, but also in fat cells and in the adrenal gland. Estrogen 
fluctuations are linked with menstruation, pregnancy, and menopause, which is why they are found in 
birth control pills and are used in hormone replacement therapies during menopause.  
 
Estrogen 
Estrogen is the primary sex hormone for women and is classified as a steroid. This allows it to 
directly diffuse through the cell membrane. Once in the cytoplasm, the hormone binds to the 
Estrogen Receptor (ER) forming an estrogen-ER complex. ERs, once activated by estrogen, are 
responsible for transporting the whole estrogen-ER complex to the nucleus where it binds to 
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estrogen response element (ERE) sequences (“Estrogen”, 2013). This binding controls protein 
synthesis by affecting the rate of transcription of estrogen responsive genes and thus the 
protein production and physiological response (Deroo, 2006). There are two known isoforms of 
cytoplasmic ERs, Estrogen Receptor α (ERα) and Estrogen Receptor β (ERβ), which vary in 
distribution throughout tissues in a given organism and play different roles dependent on the 
affinity for a specific estrogen to bind to it (Deroo, 2006). 
 
Menopause 
Estrogen levels fluctuate in women during menopause. Menopause is characterized by a time when a 
woman has been menstruation free for one year without being ill, pregnant, breast feeding or using 
medications. Approaching menopause, women go through a phase called perimenopause which lasts for 
a few years, causing irregular periods and unpredictable heavy bleeding. During perimenopause, the 
ovaries of a woman start to shrink leading to the fluctuation of estrogen and progesterone levels during 
hormone production. These hormones are responsible for menstrual cycle regulation and pregnancy 
and can cause a variety of symptoms for menopausal women (“Menopausal hormone therapy and 
cancer”, 2011). For example, estrogen deficiency causes vulvar-vaginal atrophy (VVA), and hormonal 
fluctuation causes vasomotor changes that lead to hot flashes experienced by 60% - 90% of menopausal 
women (Levine, 2011). Other common symptoms of menopause include night sweats, sleep 
disturbances, and changes in vaginal and urinary tracts (“Menopausal hormone therapy and cancer”, 
2011).  
 
Hormone Replacement Therapy 
HRT is often prescribed to women in order to help control or moderate their symptoms during 
menopause. HRT entails the intake of hormones such as estrogen, progesterone, or both in order to 
regulate fluctuating hormone levels. These hormones can be delivered in different forms such as pills, 
skin patches, creams, gels, or by intrauterine devices. Although helpful in treating some menopausal 
side effects, HRT can lead to vaginal bleeding, bloating, breast tenderness and swelling, headaches, 
mood changes, and nausea. Dangerous long term effects such as increased chance of blood clots, bone 
loss, heart attack, stroke, breast cancer, and gallbladder disease have also been observed (“Menopausal 
hormone therapy and cancer”, 2011). 
 
ET and EPT  
If a woman has previously undergone a hysterectomy, a procedure to remove the uterus in 
order to end menstrual cycles, estrogen alone is prescribed as hormone therapy. Although 
estrogen alone reduces hot flashes, bone loss, vasomotor and VVA symptoms, it is deleterious 
to the endometrium in the uterus by stimulating hypoplasia (Levine, 2011). To prevent these 
harmful effects, a combination of estrogen and progesterone is prescribed to women who have 
not undergone uterus removal. The addition of progesterone in this estrogen-progesterone 
therapy (EPT) prevents overgrowth of cells in the lining of the uterus thereby preventing 
growths that can lead to uterine cancer. Progesterone alone, however, can cause breast 
discomfort, bloating, fatigue, and depression (Levine, 2011). Therefore, the optimal menopause 
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therapy should relieve vasomotor and vulvar-vaginal symptoms, prevent fractures, have 
beneficial or neutral cardiovascular effects, and should not stimulate breast or endometrium 
cancer cell growth (Levine, 2011). 
To test the effects of HRT (estrogen therapy and EPT), randomized controlled Women’s Health 
Initiative (WHI) trials were conducted with 27,000 healthy women ages 50-79 from 40 US clinical 
centers. The two studies conducted included therapy with Estrogen Alone Therapy (ET), and 
Estrogen Progestin Therapy (EPT). In both groups, some of the women received hormone 
therapy while the others were treated with a placebo. The study was completely randomized 
and double blind. There were 10,739 postmenopausal women involved in the ET study. These 
women had hysterectomies and took a daily estrogen dose in the form of conjugated equine 
estrogen (CEE) for about six years. The effects of estrogen were then compared to the effects of 
the placebo. It was observed that estrogen therapy had neutral effects on breast cancer and 
even showed lower risks of breast cancer in those without a family history of breast cancer. The 
study showed that the risk of breast cancer was reduced by 23% (26/10,000 people per year 
versus 33/10,000 people per year), and even if breast cancer did develop, the mortality rate was 
decreased (Anderson & Limacher, 2004).  
When testing the effects of EPT, 16,608 postmenopausal women were involved where 8,506 
women were given EPT (0.625 mg/dl conjugated equine estrogens plus 2.5 mg/dl 
medoxyprogesterone acetate) and 8,102 women were treated with a placebo. Out of those 
treated by EPT, there was a 26% increase  in developing breast cancer (38/10,000 people per 
year versus 30/10,000 people per year) (Gebbie, 2002). This statistic is consistent with estimates 
from pooled epidemiological data from the Heart and Estrogen/Progestin Replacement Study 
Follow-Up (HERS II). This data reported a 15% breast cancer increase after using EPT for less 
than 5 years, and a 53% breast cancer increase after using EPT for more than 5 years, specifically 
showing a 27% breast cancer increase after 6.8 years of EPT use (Hulley et al., 2002). EPT also 
increased breast density, which made it more difficult to find breast cancer using a mammogram 
(Gebbie, 2002).  
Overall, when comparing the ET to the EPT, a cohort study of follow-up data from the Breast 
Cancer Detection Demonstration Project (1980-1995) shows a 1% increase in breast cancer with 
each year of ET, and an 8% increase in breast cancer with each year of EPT (Schairer, 2000). 
Although the WHI trial results for ET show a decreased risk in breast cancer, the question is 
raised as to how that is possible since many observational studies, such as the Breast Cancer 
Detection Demonstration Project follow-up, show that ET either increases the risk of breast 
cancer or has a neutral effect. A theory to explain this phenomenon is that breast cancer tumor 
cells can adapt to grow best at prevailing estrogen concentrations. For example, if estrogen 
concentrations are reduced in Michigan Cancer Foundation- 7 (MCF-7) breast cancer cells, 
tumor cells will stop growing at first, but will eventually adapt to the reduced concentrations 
and begin growing again. When estrogen concentrations are suddenly increased again, tumor 
growth is inhibited (Howell & Cuzick, 2012). Therefore, it is possible that after menopause, 
estrogen concentrations decline, causing tumors to adapt and grow at the new level. However, 
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they are inhibited when high estrogen concentrations are introduced via hormone replacement 
therapy. Similarly, if a woman already has breast cancer and uses high-dose estrogen treatment, 
stopping the treatment will cause a withdrawal response, which would suggest that the tumor 
adapted to grow at the higher dose (Howell & Cuzick, 2012). 
Tissue Selective Estrogen Complexes 
An ideal menopause treatment shows relief of hot flashes and VVA, maintain bone mass, and 
protect the endometrium and breast from estrogenic stimulation (Levine, 2011). An alternative 
method to ET or EPT is tissue selective estrogen complexes (TSEC). This is a new class of 
compounds that pairs a selective estrogen receptor modulator (SERM) with one or more 
estrogens in order to get tissue specific activity. This specificity should allow estrogenic action 
where it is beneficial (Mirkin & Komm, 2012).  
A type of TSEC treatment uses a combination of SERM basedoxifene (BZA) and conjugated 
estrogens (CE).  When tested on MCF-7 breast cancer cells, it was observed that BZA blocked the 
effects induced by CE, such as antiapoptotic effects, cell proliferation and growth, and protein 
and gene expression. In addition, the tissue selective agonist and antagonist activities of BZA in 
combination with CE help balance estrogenic activities in breast and endometrial tissues and 
have an overall neutral effect on these tissues.  This was also supported when BZA/CE was 
tested in mouse and non-human primate models, where BZA inhibited stimulatory activity of CE 
in breast tissues (Mirkin & Komm, 2012).  
Overall, BZA/CE treatment leads to improved post-menopausal symptoms such as reduction in 
hot flashes and VVA, increased bone mineral density, and improved quality of life, health and 
sleep. Preclinical and clinical studies show that the beneficial qualities of this treatment are 
maintained without endometrial or breast cell growth stimulation. To further test the safety of 
BZA/CE treatment, Selective Estrogen Menopause and Response to Therapy (SMART) trials were 
conducted. In these trials, the mean percent deviations from the baseline breast density at 24 
months were compared between women treated with BZA/CE and a placebo. No increase in 
abnormal breast mammograms were observed at 24 months. No differences were observed in 
breast cancer over 2 years for the BZA 20 mg/CE 0.45 mg treatment or for the BZA 20 mg/CE 
0.625 mg treatment compared with placebo. These trials, along with other studies, show that 
BZA/CE treatments are safe and effective (Mirkin & Komm, 2012).  
 
HRT is successful in lessening the strength of some menopausal symptoms. However, research has 
shown that HRT can increase the risks of many detrimental side effects such as coronary heart disease, 
osteoporosis, and breast cancer. Being aware and afraid of the negative side-effects, less than 25% of 
women receive HRT during menopause. The majority of women undergoing menopause search for 
alternative ways to self-manage their treatment. The most popular alternative is replacing HRT with 
phytoestrogens. Although research on the side effects of phytoestrogens is limited, studies are now 
starting to address the gynecologic effects of these agents in order to better define them as treatment 
(Umland, 2000).  
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 Part 2: Phytochemicals  
Phytochemicals are compounds produced by plants that can affect human health if consumed (Kurzer, 
1997). They are found in many common fruits, vegetables, beans, and grains that are commonly 
included in most diets. There are various types of phytochemicals such as carotenoids, allyl sulfides, and 
polyphenols (“e.hormone”, 2012). Carotenoids are found in many vegetables and fruits such as carrots, 
yams, and cantaloupe. They are viewed as anti-cancer agents due to Vitamin A, retinoids, and 
antioxidants. Allyl sulfides, found in garlic and onions, are thought to strengthen the body’s immune 
system. The last type of phytochemical, polyphenols, includes a large subgroup known as flavonoids. 
Flavonoids are chemicals derived from fruits, vegetables, and grains that may prevent cancer and heart 
disease. Flavonoids can act as antioxidants which rid the body of harmful molecules such as ‘free 
radicals’ through the consumption of plant products like grapes and eggplant (Cornwell, 2004). 
Additionally, isoflavonoids are a specific type of flavonoid found in red clover, garbanzo beans, and 
other plant products and are suspected to imitate the actions of estrogen (Cornwell, 2004). There is no 
substantial evidence supporting the benefits of phytochemicals, but they are being researched further.  
 
Phytoestrogens 
Phytohormones are phytochemicals that can mimic hormone signals in animals. There are twenty 
known types of phytohormones, including phytoestrogens, which mimic the female hormone estrogen. 
Phytoestrogens are studied for their potential protection against hormone dependent cancers, such as 
breast, prostate, and uterine cancer and are found in over 300 plants. Phytoestrogens are categorized 
into different chemical classes including isoflavonoids, lignans, coumestans, and stilbenes.  
Isoflavonoids 
Isoflavonoids are a subclass of flavonoids that are the most studied of the phytoestrogens. 
Isoflavonoids can exist as glucosides or as aglycones. As aglycones, they can be transported 
across intestinal epithelial cells, and as glucosides, they can be hydrolyzed to aglycones in the 
digestive system. Genistein, a commonly studied isoflavonoid, can interact with both ERα and 
ERβ to induce similar responses as estradiol in breast, ovarian, endometrial, prostate, vascular, 
and bone tissues. Genistein has also shown the ability to block cell proliferation of normal 
mammary cells, possibly decreasing the risk of breast cancer. However, when bound to ERα it 
has one third the potency of estradiol, and one thousandth the potency when bound to ERβ. 
The main source of isoflavonoids is in soy-based foods such as soy based infant formula, tofu, 
soy milk, kidney, navy and pinto beans, and chick peas (Cornwell, 2004).    
Lignans            
Lignans are phenylpropanoid dimers and oligomers, which are often not estrogenic by 
themselves, but can be converted to estrogenic mammalian lignans. This conversion of plant 
lignans (secoisolariciresinol and matairesinol) to mammalian lignans (enterodiol and 
enterolactone) occurs in the gastrointestinal tract as a result of bacterial action (Kurzer, 1997). 
Both enterodiol and enterolactone bind to ERα and ERβ with a higher affinity for ERβ. Lignans 
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are found in high concentrations in flaxseed, whole grain breads, vegetables, and tea. They can 
also be found in low concentrations in fruits; however, they are not found in strawberries or 
cranberries (Cornwell, 2004). 
Coumestans 
Coumestans can be found in large numbers; however, very few (coumestrol and 
4’methoxycoumestrol) have been known to show estrogenic activity (Cornwell, 2004). Studies 
have shown that coumestrol has a higher affinity than estradiol for binding to ERβ. The highest 
concentration of coumestrol can be found in clover and soybean sprouts and low levels can be 
found in legumes, Brussels sprouts, and spinach (Cornwell, 2004). 
Stilbenes 
The primary dietary source of stilbenes is resveratrol, a phytoalexin, which accumulates at areas 
of pathogen infection. Only the trans isomer of resveratrol has been found to be estrogenic, and 
it has a much higher affinity for interacting with ERβ than ERα. Resveratrol has also shown 
agonistic and antagonistic activity in MCF-7 cells in the hamster ovarian cell line (CHO-K1) that 
was transfected with human ERs. Resveratrol is primarily found in peanuts as well as the skin of 
red grapes and products such as juice and wine. However, the processing of these foods has an 
effect on the amount of resveratrol found in the final product. For example, grapes have a 
higher content of resveratrol than grape juices, and boiled peanuts have a higher concentration 
than peanut butter or roasted peanuts (Cornwell, 2004).  
 
Phytoestrogens in Daily Diets  
Since phytoestrogens are found in various plants and plant products, humans ingest the chemicals 
naturally through diet. Daily intake from vegetables, beans, grains, and seeds is not detrimental to the 
body and may even be seen as beneficial; however, consuming excess phytoestrogens through dietary 
supplements may have varying effects. Infants who drink soy formula have the highest level of 
phytoestrogens while adults on vegetable diets intake the next highest amount (Kurzer, 1997). When 
comparing the health of Westerners and Asians, it appears that a diet including phytoestrogens can aid 
in cancer prevention and treatment of menopausal symptoms (Hilakivi-Clarke et al., 2010). This 
conclusion was made when combining the work of Trock et al. and Wu et al. (Trock et al., 2006; Wu et 
al., 2008).  
In the Trock et al. study, Westerners and Asians were given a high soy diet in order to observe the 
effects on breast cancer. The study indicated that the intake of soy by Westerners was associated with a 
reduced breast cancer risk and was most prevalent among premenopausal women. However, the Asian 
women did not see any significant reduction. Wu et al. performed a similar study using the categories 
Westerners and Asian women, but found the opposite results (Wu et al., 2008). Western women did not 
have any risk reduction, but the Asian women did. The source of confusion stems from the classification 
of the women in the study; Trock et al. included Asian Americans in his Western category whereas Wu et 
al. included them in the Asian category. Therefore, when combining these results, it was concluded that 
Asian American women see a protective effect by consuming moderate levels of soy on a daily basis 
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whereas Asians who adopt the Western dietary habits later in life do not see protection (Hilakivi-Clarke 
et al., 2010). This is because Asians would be going from a high soy intake to a low soy intake which 
would put them at a higher risk for breast cancer, whereas Asian Americans who already had a Western 
diet are eating more soy resulting in breast cancer risk reduction (Hilakivi-Clarke et al., 2010). 
In addition to the amount of phytoestrogens consumed, the time period in which someone is exposed 
may also be important. When exposed early in life through diet, phytoestrogens may be cancer 
preventative, but the effects of ingestion during adulthood are less clear (Warren, 2001). This is 
inconclusive due to studies that propose phytoestrogens as a health benefit and contradictory results 
showing them as a health risk. Results from some of these studies are presented below. 
Health Benefits 
In a study done on postmenopausal Japanese women, participants have reportedly experienced 
reduced vasomotor symptoms of menopause such as hot flash frequency and severity. There 
was a 30% - 50% reduction in hot flashes when soy isoflavonoids were taken in several doses 
throughout the day. However, this total percentage includes the 10% - 20% of participants given 
a placebo who also reported a reduction. This limits the actual benefits to a 20% - 30% reduction 
of hot flashes which is still a significant percentage, but not as substantial as the study had 
postulated (Hilakivi-Clarke et al., 2010). 
Another possible benefit of phytoestrogens includes cardiovascular health. The effects of a diet 
low in saturated fat and cholesterol with 25g of soy protein per day on the risk of heart disease 
were tested (Lissin et al., 2000). It was found that an average intake of 47g per day of soy 
protein decreased total cholesterol by 9%, decreased Low Density Lipoprotein (LDL) by 13%, and 
showed a trend toward increased High Density Lipoprotein (HDL). To determine the role of 
isoflavonoids in the control of cholesterol, a study compared participants receiving soy protein 
containing its natural isoflavonoids and participants receiving soy that was stripped of its 
isoflavonoids (Lissin et al., 2000). These studies suggested that isoflavonoids were required for 
the desired results in cholesterol levels. 
Although there have been studies to support both reduction in postmenopausal symptoms and 
increased cardiovascular health, the results may be the cause of other factors. Since the plant 
products consumed in these studies were not just phytoestrogens but also included protease 
inhibitors and antioxidants, the results could be due to these other ingredients (Kurzer, 2003). 
Additionally, since the study on reduced hot flashes was done on Asian women, there may be 
some adaptation that they have acquired through years of high soy intake providing them with a 
better response to phytoestrogen supplements than Westerners (Kurzer, 2003). 
Health Risks 
Conversely, phytoestrogens can also pose a health risk. High exposure to estrogen over a 
lifetime is linked to increased breast cancer risk, so if phytoestrogens bind through the same 
pathway, they may also pose a risk. A study was conducted using estrogen responsive breast 
cancer cells treated with low doses of phytoestrogens extracted from soymilk (Dip et al., 2013). 
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mRNA analysis revealed that the phytoestrogen induced tumor-promoting transcriptional 
signaling was indistinguishable from that of estrogen (Dip et al., 2013). This increase in signaling 
led to proliferation of tumor cells showing that phytoestrogens can pose a health risk at certain 
doses (Dip et al., 2013). Additionally, the estrogen-like properties may cause reproductive 
problems such as infertility and developmental issues (Kurzer, 2003). Many historical plants 
documented to prevent pregnancies or cause miscarriages were tested and found to contain 
phytoestrogens or other phytohormones. It is thought that plants began producing compounds 
that when ingested by herbivores would limit their reproduction, resulting in a reduced 
predation of that plant species (Kurzer, 2003). 
 
The health benefits and risks mentioned above provide strong evidence that phytoestrogens need to be 
studied further. Although it is clear that phytoestrogens in an everyday diet are not detrimental to the 
body, there is little conclusive data regarding their use as dietary supplements marketed as a safe 
alternative to HRT. 
 
Part 3: Food and Drug Administration 
In order for any drug to be legally sold in the United States, it must be approved by the Food and Drug 
Administration (FDA). Since its inception in 1906 under the Department of Health and Human Services, 
the FDA has regulated over $1 trillion worth of products. The FDA is responsible for the safety of foods, 
tobacco, electronic device radiation, vaccines and drugs. The drug category encompasses over the 
counter and prescription medications for both human and veterinary use (“What does FDA do?”, 
2013).     
 
Over the Counter Drugs 
Over the counter drugs (OTC) are medications that may be purchased without a prescription. The list of 
what constitutes an OTC is vast. Some examples include vitamins, dietary supplements, allergy 
medication, and painkillers. They are available at pharmacies as well as health supplement stores such 
as GNC and Vitamin World. The majority of phytoestrogens are sold this way.  
Over the counter drugs are monitored by the Office of Drug Evaluation and the Nonprescription Drug 
Advisory Committee. These groups monitor the safety and efficacy of the drugs and the appropriateness 
of their labels as well as determine the contents of drug monographs. A drug monograph is like a recipe 
that describes the acceptable parameters and ingredients for medications by class. For instance, there 
may be a monograph simply for antacids, not a specific brand or type of antacid. If an OTC falls 
completely within the constraints of the correct monograph for its category, then that medication can 
go to market directly (“OTC, Nonprescription”, 2013). 
The drug monograph is created through a three-phase process in which the findings are continually 
tested and reviewed. In the first phase, the active ingredients, appropriate dosages, side effects, and 
repercussions of misuse are examined and approved by advisory review (Over-the-Counter (OTC) Drug 
Monograph Process, 2013).  The findings are published in the Federal Register In the format of an 
Advanced Notice Proposed Rulemaking (ANPR). Once the findings are published, they are once again 
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open for review and any qualified and interested person or group can formally submit comments. 
Following this review, the active ingredients may be categorized into one of three groups: 
 
● Category I: generally recognized as safe and effective for the claimed therapeutic indication; 
● Category II: not generally recognized as safe and effective or unacceptable indications; 
● Category III: insufficient data available to permit final classification (“Over-the-Counter (OTC) 
Drug Monograph Process”, 2013). 
 
Once the category is selected, phase two begins. Similar to the first phase, the review process begins.  
This time, reviewers must take the previous panel’s review, public comment, and any new relevant data 
into account.  The OTC Drug Review panel then publishes its findings as a tentative final monograph 
(TFM) in the Federal Register. Once there, it is made public again and is up for review and comment 
from interested groups (“Over-the-Counter (OTC) Drug Monograph Process”, 2013). 
The monograph is finalized in the third phase. Like in the previous phases, the comments, additional 
data, and anything else relevant brought to light must be considered. The final monograph contains the 
appropriate active ingredients, labeling guidelines, and dosage suggestions that were verified to safely 
treat the ailment the OTC drug is targeting. A final monograph is not set in stone.  As new data and more 
safe and effective active ingredients emerge, it may become desirable to amend a monograph. The 
public can do this by submitting a petition, or it can occur more directly by the Drug Review 
Commissioner (“Over-the-Counter (OTC) Drug Monograph Process”, 2013). 
If an OTC does not fall within the proper monograph, the manufacturer must go through the New Drug 
Evaluation process. Prescription drugs that are applying to become OTC may require going this route. 
This process is extremely long and requires FDA observation throughout development. Based on this, it 
is easier for OTC drugs to be made via the monograph process, which does not require FDA pre-approval 
before going to market (“OTC, Nonprescription”, 2013).  
 
FDA Regulations for Dietary Supplements 
Phytoestrogens are typically sold as “dietary supplements,” which are not governed as strictly as 
substances classified as “drugs” by the FDA. Although the guidelines governing the production and 
composition of dietary supplements are much more lenient, evidence has shown that these 
supplements can have severe and lasting effects on the human body. The popularity of dietary 
supplements has skyrocketed over the last few decades, leading to an abundance of controversies 
regarding their potentially harmful effects. Due to the potential hazards of dietary supplement use, it is 
vital to test these medications and hold them to higher standards than those required by the FDA. 
Today, all dietary supplements distributed in the United States must follow the guidelines described in 
the FDAs Current Good Manufacturing Practices (CGMPs). This set of rules prevents many potential 
hazards by requiring both foreign and domestic manufacturers to ensure supplements are free of 
contaminants and are accurately labeled. As a general rule, any substance marketed as a dietary 
supplement prior to October 15, 1994 that has been deemed safe by the FDA is allowed in modern 
supplements. Manufacturers must have a reasonable expectation that new dietary ingredients (anything 
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marketed as a supplement after October 15, 1994) are safe for consumption, and these ingredients 
must be reported to the FDA (“New Dietary Ingredients”, 2013). Additionally, any serious adverse 
reactions to dietary supplements must be reported to the FDA. The final ruling on these CGMPs was 
enacted on June 22, 2007, making all of these guidelines mandatory by law (“Final Rule”, 2013). A 
statement from the FDA summarizing CGMPs was then released to the public: 
“The final rule aims to ensure that dietary supplements do NOT have wrong ingredients; too 
much or too little of a dietary ingredient; improper packaging; improper labeling; contamination 
problems due to natural toxins, bacteria, pesticides, glass, lead, or other substances” (“Final 
Rule”, 2013). 
 
These guidelines have lead Americans to feel secure in their decisions to buy and consume dietary 
supplements, but leniencies in the laws have allowed dangerous substances to be marketed as 
supplements numerous times. 
One potentially dangerous discrepancy in CGMPs is that manufacturers are not required to register new 
products with the FDA prior to production and distribution. Although the manufacturers are expected to 
follow the FDA’s guidelines, the Dietary Supplement Health and Education Act of 1994 (DSHEA) ruled 
that dietary supplements are regulated similarly to food rather than drugs, so there is no strict quality 
control by the government before new products are released. Instead, it is the manufacturers’ 
responsibility to provide the FDA with some evidence that their products are safe (“Final Rule”, 2013). 
This increases the chance of hazards resulting from companies that are negligent, dishonest, or unaware 
of dangers in their products. Dietary supplements are created and sold by many foreign or 
inexperienced companies that cannot be trusted to ensure the quality, potency, or purity of their 
products. 
Poorly regulated dietary supplements have been the cause of many serious health problems for 
Americans. The most notable of these situations is the use of ephedra and ephedrine in weight loss 
supplements and athletic performance enhancers, which gained extreme popularity in the 90s (Beckner, 
n.d.). Ephedrine, the alkaloid extract from the plant Ephedra sinica, is still sought after today by weight 
loss fad followers, even though there has been no sufficient evidence showing that it is safe or even 
effective for long-term use. Controversies arose when studies showed that ephedrine use is associated 
with 2 to 3 fold increases in psychiatric symptoms, autonomic symptoms, upper gastrointestinal 
symptoms, and heart palpitations. A paper released by the Journal of the American Medical Association 
in 2003 pointed out 5 deaths, 5 myocardial infarctions, 11 cerebrovascular accidents, 4 seizures, and 8 
psychiatric cases that were linked to the use of ephedrine in dietary supplements (“The Need for 
Regulation of Dietary Supplements”, 2003). Despite these telling studies, ephedrine and similar products 
are still popularized and desired by many Americans. 
Even when dietary ingredients themselves are deemed “safe” by the FDA, other complications can pose 
health hazards to dietary supplement users. For example, the lack of regulation often leads to incorrect 
dosage. Additionally, the amount of each supplement listed on the label does not always accurately 
reflect the amounts in the supplements themselves. Interactions between botanical ingredients and 
prescription medications can also cause complications for users. Furthermore, irresponsible 
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manufacturers sometimes neglect to report adverse effects of their products. It is estimated that only 
about 10% of serious side effects are properly reported to the FDA (Marcus, 2002). Possibly the most 
concerning aspect of dietary supplement regulation is that pharmaceuticals and heavy metals can evade 
quality control measures, putting supplement users’ health in serious danger. A comprehensive study of 
patented dietary supplements from Asia sold in California in 1998 produced alarming results. About 32% 
of these products were found to contain undeclared pharmaceuticals, such as clorpheniramine and 
phenacetin, or heavy metals like lead, mercury, and arsenic (Marcus, 2002). Although time has passed 
since the biggest controversies regarding dietary supplements occurred, there are still many loopholes 
in the regulation processes that endanger the American public.  
By executing extensive safety tests on a series of phytoestrogen-based dietary supplements, this study 
aims to reveal unknown potential health benefits and hazards for those using these substances in their 
daily lives. The results of these tests, in addition to the information provided about current FDA 
regulations, could be used to suggest improvements in the government regulation processes for dietary 
supplements as a whole. A primary focus of this study was observing the effects of phytoestrogens on 
the T47D-KBluc breast cancer cell line.  
 
Part 4: Phytoestrogens and T47D-KBluc Cell Line  
In this study, three commercial OTCs, black cohosh, red clover, and grape seed extract, were tested for 
their proliferative and anti-proliferative effects on T47D-KBluc breast cancer cells. 
Black Cohosh 
Black cohosh, commonly known as Cimicifuga racemosa Nutt, is generally used as an herbal remedy of 
symptom relief during and after menopause-like flashes and sweats, joint aches, and headaches. Black 
cohosh is a part of the isoflavonone family and contains the ingredient isoflavonone formononetin.  
In vitro studies have reported black cohosh to possess inhibitory effects on proliferation of estrogen 
responsive breast cancer cells. Gaube et al. performed experiments using black cohosh extract in 
dichloromethane (Gaube et al., 2007). The extract was applied to MCF-7 breast cancer cells for 72 hours 
at which time the media was changed and the cells were allowed to grow for another 120 hours. The 
MTT assay conducted revealed that black cohosh treated cells responded conversely to treatment with 
β-estradiol, showing no cell proliferation. Additionally, the extract caused downregulation of the ERα 
mRNA which can result in antitumor activity (Gaube et al., 2007).  
A second study performed by Al-Akoum et al. demonstrated the anti-proliferative effects of black 
cohosh extract on MCF-7 cells (Al-Akoum et al., 2007). Al-Akoum et al. also observed the effects of the 
ER antagonist tamoxifen which binds to the receptor and blocks the active site. Adding various 
concentrations of tamoxifen to β-estradiol treated cells inhibited the proliferative effects seen without 
the antagonist. Additionally, when added to black cohosh, tamoxifen contributed further to the 
inhibition of breast cancer cell growth. Black cohosh was also added to β-estradiol treated cells resulting 
in a dose-dependent inhibition of the β-estradiol’s proliferative effects (Al-Akoum et al., 2007). 
There are contradicting findings by Ji et al. and Halabalaki et al. These studies used formononetin 
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extracted from black cohosh and purified. Both found that formononetin is estrogenic in a concentration 
dependent manner from 0.5 to 500 µM on an estrogen responsive MCF-7 line (Ji et al., 2005; Halabalaki 
et al., 2006).  
Although there were conflicting studies, the results of Al-Akoum et al. and Gaube et al. led to the 
decision to use black cohosh as a negative control. 
Grape Seed 
Grape seed is a nutraceutical that belongs to the bioflavonoid family. It is composed of chains of 
procyanidins that are found in a wide variety of beverages and foods such as fruits and cereal grains. 
A study conducted using grape seed focused on the effect of bioflavonoid on the highly metastatic MDA-
MB231 breast cancer cell line, concentrating on cell invasion and migration. It was observed that high 
concentrations of flavonoid inhibited cell proliferation and apoptosis, while low concentrations of 
flavonoid decreased migration and invasion (Dinicola et al., 2013). Another study observed the effect of 
grape seed on MCF-7 breast cancer cell proliferation and expression of the gene survivin. It also 
investigated the molecular, biological mechanism of inhibition by grape seed. The results revealed that 
grape seed inhibits the proliferation of the MCF-7 cells through arresting the cell cycle in S phase (Chen 
et al., 2009). 
From these studies, the effects on breast cancer activity caused by grape seed extract are concentration 
dependent. The effects of this extract on proliferation were varied; therefore, black cohosh was a more 
logical choice for a negative control. 
Red Clover 
Red clover is a member of leguminosae family and is also known as Trifolium pretense. Red clover 
contains high levels of all four major forms of isoflavonoids – formononetin, biochanin, daidzein, and 
genistein. Of these, the most active components in red clover are biochanin and genistein (Albulescu, 
2006). 
 
Historically, red clover has been used by post-menopausal women for various reasons including hot 
flashes, night sweats, reduced libido, vaginal dryness, cyclic breast pain or tenderness, cancer 
prevention, indigestion, whooping cough, cough, asthma, bronchitis, and maintaining bone density. 
A study conducted by Reiter et al. isolated isoflavonoids from red clover and observed their effects on 
eleven types of cancer cells, including breast cancer. Their findings showed that these isoflavonoids, 
primarily genestein, promoted cell cycle arrest and apoptosis (Reiter et al., 2011). One study on red 
clover showed that women aged 49 - 65 taking 26 mg biochanin A, 16 mg formononetin, 1 mg genistein, 
and 0.5 mg daidzein daily for one year did not increase their mammographic breast density (Atkinson et 
al., 2004). Another study on MCF-7 cells revealed increased proliferation in response to the biochanin A 
component of red clover at concentrations less than 0.1 µM. However, the same cell line proliferation 
was inhibited when the concentration was increased to 20 µM (Wang, 1995). Finally, a study showed 
that genistein activated an estrogen response element in Ishikawa cells and biochanin A induced 
luciferase in MCF-7 cells (Overk et al., 2005). 
 17 
These studies taken together show that red clover is also dose dependent at inducing breast cancer cell 
proliferation. The dose dependent response to red clover contributed to the choice of black cohosh as 
the negative control.  
 
T47D-KBluc Cell line 
The T47D-KBluc cell line from American Type Culture Collection is used in these experiments (T47D-
KBluc, 2013). T47D cells are from the ductal carcinoma of mammary gland, breast/duct derived from 
pleural effusion of a 54 year old female. This cell line is used to screen chemicals for estrogenic or anti-
estrogenic activities as they are reported to have an affinity for ERα and ERβ. Various studies established 
that the cell line is highly responsive to estrogen, which is important because it allows research of 
phytoestrogenic responses as well (Wilson et al., 2004).  
T47D-KBluc is the fluorescent variation of the T47D cell line. It was developed by transfecting T47D cells 
that contain both ERα and ERβ with estrogen response element, the luciferase reporter gene construct 
(Wilson et al., 2004).  
Conclusion 
The effects of menopause on a woman’s body due to hormone fluctuations are detrimental, and efforts 
to minimize these side effects are progressing. Replacing HRT with phytoestrogen treatment remains in 
the preliminary steps. Further research and development of phytoestrogens needs to be completed in 
order to classify them as a safe and effective treatment for menopause symptoms. One of the most 
detrimental side effects of HRT is the increased risk of breast cancer, which needs to be taken into 
account when dealing with phytochemicals that respond through the same receptors. There are very 
few conclusive studies on phytoestrogens’ proliferative effects on breast cancer cells and many such 
studies contradict each other. The experiments described in this paper will shed light on the effects of 
three different over the counter phytoestrogen pills sold currently: black cohosh, red clover, and grape 
seed. Extracts of these supplements containing phytoestrogens will be tested for proliferative effects on 
breast cancer cells, then certain chemicals within the pill will be analyzed. 
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Methods 
Extraction of Supplements 
Based on the processes outlined by Setchell et al. (2001), the supplements were extracted from the 
capsules they were commercially available in. The purpose of this process was to obtain liquid samples 
of each phytoestrogen that could be used in the High Performance Liquid Chromatography (HPLC) 
process and administered onto cells. 
Black Cohosh 
One 540 mg capsule of Nature’s Way Black Cohosh was opened and the contents were added to 80 mL 
of 80% volume per volume methanol in an Erlenmeyer flask and mixed. The solution was then 
transferred to a round bottom flask and attached to a water-jacketed reflux condenser. The solution was 
refluxed for approximately 60 minutes at a boiling point of 65oC, which is the boiling point of methanol. 
After the reflux, the sample was filtered using a Drummond 0.8 µL filter and stored at -20oC in two 50 
mL tubes in the dark. 
Red Clover 
The same procedure as above was followed, however using one 400 mg capsule of Nature’s Way Red 
Clover. 
Grape seed Extract 
The same procedure as above was followed, however using one 300 mg capsule of Nature’s Way Grape 
seed Extract. 
 
High Performance Liquid Chromatography 
HPLC was performed according to the procedures outlined in Setchell et al. (2001) and Jessica Caron’s 
Thesis (2007) in order to determine the contents of each phytoestrogen supplement. 10 µl of grape seed 
extract, as well as the phytoestrogen standards genistein, diadzein, and resveratrol, were injected at a 
rate of 1 mL/min onto a reverse phase C18 250 X 4.6 mm column, while black cohosh and red clover 
were increased to 50 µl and 100 µl respectively due to initial lack of sufficient signal. The standards were 
at a concentration of 100 µM. Following this injection; the column was washed with a solution 
containing 10 mM ammonium acetate and 0.1% trifluoroacetic acid (TFA) for two minutes. For the 
subsequent 22 minutes, the column was eluted with a linear gradient of the ammonium acetate TFA 
solution and acetonitrile, during which time the ammonium acetate and TFA ran between 100% - 50% 
and acetonitrile ran between 0% - 50%. The column was then held isocratic for the remaining five 
minutes of the run, followed by 100% 10 mM ammonium acetate, 0.1% TFA for a six minute re-
equilibration. The absorbances of the samples at 260 nm were recorded and generated in a 
chromatogram. 
The chromatograms show peaks for the times at which different compounds were eluted, and the 
absorbances (mAU) of the compounds. The chromatograms of red clover, black cohosh and grape seed 
extracts were observed and compared to the chromatograms of phytoestrogen standards. In order to 
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identify whether the extracts contained phytoestrogen standards, the extracts were spiked with each 
standard. Since the extracts did not contain any of the phytoestrogen standards, then the most 
prominent peaks were collected. Prominent peaks were identified as those with the largest percentage 
of the total area. Peak collection started at the start of the peak of interest, and stopped 15 seconds 
after the end of the peak.    
 
Serial Dilutions 
After extraction, the stock solutions of black cohosh, grape seed, and red cohosh were diluted for 
concentration dependent testing later. Five 10-fold dilutions were completed using the stock solution 
and 95% methanol. Five 1.5 mL eppendorf tubes were labeled with the extract name and dilution 
number and 900 µL of 95% methanol were added to each. 100 µL of the stock solution is added to the 
first dilution tube raising the volume up to 1 mL with 1 part stock solution and 9 parts methanol. After 
mixing thoroughly, 100 µL of the first dilution was added to the next tube containing 900 µL of methanol 
making the second 10-fold dilution. This is done three more times until the fifth dilution was made and 
completed for the three extracts, β-estradiol, black cohosh peak, grape seed peak, and red cohosh peaks 
1, 2, 3, and 4. The dilution is depicted in Table 1 below. 
Black Cohosh D1 Black Cohosh D2 Black Cohosh D3 Black Cohosh D4 Black Cohosh D5 
100 µL BC Stock 
+ 
900 µL Methanol 
100 µL BC D1 
+ 
900 µL Methanol 
100 µL BC D2 
+ 
900 µL Methanol 
100 µL BC D3 
+ 
900 µL Methanol 
100 µL BC D4 
+ 
900 µL Methanol 
Table 1: Black Cohosh 10-fold Dilution with 95% Methanol 
 
MTT Assay 
A CellTiter 96 well flat bottom plate was used for the MTT assay. Each well received 104 cells plated in 
100 µL DMEM with 10% FBS, 1% glutamine, and 1% Penicillin Streptomycin (Pen/Strep). The cells were 
allowed to attach to the plate for 24 hours at which time the media was aspirated and replaced with 
100µL Phenol Red Free DMEM with 5% dextran-charcoal treated FBS (PHRED). The cells were allowed to 
equilibrate in PHRED for 24 hours before chemicals were applied. 
Five 10-fold serial dilutions of β-estradiol, grape seed extract, black cohosh, and red clover stock 
solutions were made in 95% methanol. The layout of the 96 well plate is depicted in Table 2. Methanol 
was used as a control since it was the solvent used to make the dilutions of b-estradiol and the 
phytoestrogen samples. A media alone control (blank) was also run to observe the baseline cell growth. 
After the 24 hour equilibration, the PHRED was aspirated and replaced with fresh PHRED along with 1 µL 
of each sample, according to Table 2, and incubated for another 24 hours. 
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Control 
Blank 
Control 
Methanol 
b-estradiol Grape Seed Black Cohosh Red Clover 
100µL media + 100µL media + 100µL media + 100µL media + 100µL media + 100µL media + 
0µL Stock 0µL Stock 1µL Stock 1µL Stock 1µL Stock 1µL Stock 
1µL Stock 1µL Stock 1µL D1 1µL D1 1µL D1 1µL D1 
    1µL D2 1µL D2 1µL D2 1µL D2 
    1µL D3 1µL D3 1µL D3 1µL D3 
    1µL D4 1µL D4 1µL D4 1µL D4 
    1µL D5 1µL D5 1µL D5 1µL D5 
Table 2: The layout for the 96 well plate used for the MTT assay 
Once the cells were exposed to each supplement for 24 hours, 20 µL of CellTiter 96 Aqueous One 
Solution Reagent (Promega) was added to each well followed by incubation for another 2 - 4 hours. At 
this time, the 96 well plate was placed in a spectrophotometric plate reader and the absorbance for 
each well was read at 570 nm. The absorbances from wells containing no cells were averaged and 
subtracted from each well reading to normalize the numbers. 
Additionally, the MTT assay was run with the same controls and extracts used in Table 2, but with the 
addition of the peaks for each extract. Five 10-fold dilutions were made for the black cohosh peak, grape 
seed peak, and red clover peaks 1, 2, 3, and 4. Alternatively, the assay including the peaks was 
completed with a second brand of MTT reagent, TACS MTT Cell Proliferation Assays (Trevigen). After the 
24 hours with each supplement, 10 µL of TACS reagent was added to each well and incubated for 2 - 4 
hours. At this time, 100 µL of Detergent Reagent was added to each well and the plate was again 
incubated for 2 - 4 hours. The absorbances were read using the same plate reader at 570 nm. 
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Results and Discussion 
 
HPLC Results 
The purpose of this project was to analyze the components of the three over the counter phytoestrogen 
supplements: red clover, grape seed, and black cohosh. In order to gain a better understanding about 
their composition, the three extracts were separated by HPLC according to the HPLC procedure in the 
Methods Section.  After the HPLC was completed, a chromatogram was generated, and used to analyze 
the data.  The x-axis on the chromatogram depicts the time in minutes that it took to separate the 
components of the sample. The y-axis shows the mass absorbance unit (mAU), which represents the 
height of the peaks. In addition, the chromatogram analyzes the width and height of the peak, the area 
beneath the peak, and the percent of the total area that each peak takes up. These measurements, 
found in Table 3, were used in order to determine the major peaks, which represent the main 
components of the extracts. 
Sample Peaks Time (min) Height 
(mAU) 
Width 
(min) 
Total Area 
(mAU*s) 
% Total Area 
Black Cohosh 11 16.8 45.37 0.46 1711.52 35.00 
Grape Seed 1 3.6 2454.15 0.40 72231.50 89.56 
Red Clover  1-2 3.26-3.71 181.17 0.40 5138.70 21.03 
Red Clover  13-19 15.56-18.31 305.10 0.84 2752.94 11.27 
Red Clover  28-29 21.56-22.14 241.47 0.55 5150.69 21.09 
Red Clover  35 27.6 226.74 0.32 5567.18 22.79 
Table 3: Chromatogram Peak Measurements 
Figure 1 below depicts a chromatogram showing the HPLC of black cohosh extract. Based on the 
measurements shown in Table 3, the most prominent peak is Peak 11 at 16.80 minutes. This peak is the 
largest and comprises 35% of the total area.  
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Figure 1: Chromatogram of Black Cohosh Extract 
 
Figure 2 below depicts a chromatogram showing the HPLC of grape seed extract. Based on the 
measurements shown in Table 3, the most prominent peak is Peak 1 at 3.60 minutes. This peak is the 
largest and comprises 89.56% of the total area.  
 
 
Figure 2: Chromatogram of Grape Seed Extract 
 
Peak 1 
Peak 11 
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 Figure 3 below depicts a chromatogram showing the HPLC of red clover extract. According to the 
measurements shown in Table 3, the most prominent peaks are Peaks 1 and 2 at 3.26 to 3.71 minutes, 
Peaks 13 through 19 at 15.56 to 18.31 minutes, Peaks 28 and 29 at 21.56 through 22.14 minutes and 
Peak 35 at 27.60 minutes. The combination of Peak 1 and 2 takes up 21.03% of the total area. The 
combination of Peaks 13 through 19 comprises 11.27% of the total area. The combination of Peaks 28 
and 29 comprise 21.09% of the total area. Finally peak 35 comprises 22.79% of the total area, making it 
the largest peak. 
 
 
Figure 3: Chromatogram of Red Clover Extract 
 
In order to compare the prominent peaks with known phytoestrogen samples, known standards were 
run. These standards were daidzein, resveratrol, and genistein and can be found in Figures 4, 5, and 6 
respectively. 
Figure 4 below shows the standard daidzein. The only peak in the daidzein chromatogram occurred at 
19.903 minutes. This peak did not correspond to the prominent peaks determined for any of the 
extracts, meaning that daidzein is either not present in these extracts, or if it is present, it does not 
occur in large amounts. For example, in the grape seed extract the most prominent peak is at 3.598 
minutes, but there is a small peak observed at 19.932 minutes which only amounts to 0.3247% of the 
total area. This peak could be daidzein, however it is present in very small amounts compared to the 
other compounds.  
 
Peak 1-2 
Peak 13-19 
Peak 
28-29 
Peak 35 
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Figure 4: Chromatogram of Daidzein 
 
Figure 5 below shows the HPLC data for the standard resveratrol. Based on this HPLC, resveratrol 
contains four overlapping peaks that occurred in the short span between 18.819 minutes and 19.111 
minutes. This collection of peaks did not correspond to the prominent peaks determined for any of the 
extracts, meaning that resveratrol is either absent from these extracts, or if it is present, it does not 
occur in large amounts. For example, in the red clover extract, the most prominent peaks are from 
15.563 to 18.305 minutes and 21.561 through 22.142 minutes, but there are small peaks observed at 
18.857 and at 19.045 minutes which only amount to 0.0793% and 0.2766% of the total area 
respectively. These peaks overlap with part of the resveratrol peak and therefore could be resveratrol; 
however, it would be present in very small amounts.  
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Figure 5: Chromatogram of Resveratrol 
 
Figure 6 below shows the HPLC data for the standard genistein. The only peak in the genistein 
chromatogram occurred at 22.633 minutes. This peak did not correspond to the prominent peaks 
determined for any of the extracts, meaning that genistein is not visibly present in any of the extracts.  
 
Figure 6: Chromatogram of Genistein 
 
The absence of peaks in the red clover extract HPLC corresponding to genistein and daidzein is 
inconsistent with the findings in the background research (Albulescu et al., 2006; Reiter et al., 2011). 
Albulescu et al. reports isolating daidzein and genistein from purified red clover extract, but did not 
provide HPLC data for comparison purposes. Reiter et al. reported the isolation of isoflavonoids, 
primarily genistein, from red clover without including HPLC data either. The previous research 
conducted on black cohosh and grape seed components did not reveal the presence of the three 
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standards tested (Chen, 2009). Therefore, the absence of peaks during these experiments was as 
expected. Overall, the absence of daidzein, genistein, and resveratrol in the samples only rules out the 
lack of three known phytoestrogens, but others may be present. 
Although the phytoestrogen supplements did not contain the known phytoestrogen standards in large 
amounts, the prominent peaks determined were collected for each supplement to test the effects of 
each compound present on the breast cancer line T47D-KBluc. Most of the smaller peaks in the 
chromatograms were not collected because the large peaks were focused on. It is possible that the 
compounds represented by the smaller peaks have greater effect on the cells. In the case of resveratrol, 
four overlapping peaks were observed in Figure 5 as one large peak. However, these peaks could be 
analyzed separately by using alternative solvents, slowing the flow rate, and using a different column. 
Similarly, red clover had many overlapping peaks making the collection process difficult. Further 
resolution of these peaks is necessary to see the individual effects of the overlapping peaks on cell 
proliferation.   
Table 4 below shows the comparison between the peaks found in at least two extracts, which eluted 
less than 0.05 minutes apart. Black cohosh and red clover had the most compounds in common. The size 
and shapes of the compound peaks were also similar.  These peaks should be analyzed in future 
experiments.   
Black 
Cohosh 
3.29 6.62  9.96 10.37 13.36  16.83 18.61 18.89 26.28 
Red 
Clover 
3.26 6.65 9.48  10.38  14.61 16.8 18.61 18.85 26.28 
Grape 
Seed 
  9.49 9.98  13.32 14.63     
Table 4: Compound comparison among the extracts 
MTT Assays 
An MTT assay is used to determine cell proliferation in the presence of phytoestrogen extracts at various 
concentrations. The peaks collected from HPLC were also tested on the cells to observe effects on 
proliferation. In this section, the extract and peak effects on proliferation will be compared to the 
proliferative effects of β-estradiol, the positive control. After the assay was completed, the plates were 
read using a spectrophotometer at 570 nm and these results were graphed versus the proliferation of 
untreated cells (blank). Each data point was graphed based on the stock concentration then three or 
four subsequent tenfold dilutions. 
 
CellTiter 96 
The first MTT assay performed used the CellTiter 96 method (see MTT Assay Methods) for β-estradiol, 
black cohosh extract, grape seed extract, and red clover extract.  
β-estradiol was used as a positive control for this experiment because it is known to cause proliferation 
of breast cancer cells. The maximum concentration of β-estradiol used in this experiment was 0.1 nM, 
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which is directly comparable to the estrogen concentration of Wilson et al.  The stock solution of β-
estradiol in this assay had an absorbance reading of 0.715, which was the highest proliferation detected 
during this assay and can be seen below in Figure 7. When comparing the results shown here to Wilson 
et al., the same proliferative effects were observed. For both assays, the proliferation stays at baseline 
from concentrations 1x10-5 nM to 1x10-3 nM and began its ascent at 1x10-3 nM (Wilson et al., 2004). This 
similarity validates the CellTiter 96 assay results presented here. 
 
 
Figure 7: CellTiter 96 MTT Assay Reading of β-estradiol Extract at 570nm 
The results for proliferation of breast cancer cells treated with black cohosh extract consistently stayed 
near baseline. The linear trendline of black cohosh, seen in Figure 8, extract indicates little difference in 
growth of treated cells compared to those not treated. Black cohosh was used as a negative control due 
to research performed by Al-Akroum et al. and Gaube et al. (Al-Akroum et al., 2007; Gaube et al., 2007). 
Through these studies, it was concluded that black cohosh has antiproliferative effects. The negligible 
deviation from baseline in comparison to the substantial growth of the positive control, β-estradiol, 
supports these findings. Although the results were similar, the extraction procedures and exposure time 
differed between experiments. Gaube et al. exposed the breast cancer cells to black cohosh extract in 
dichloromethane for 72 hours then allowed growth for an additional 120 hours, whereas this 
experiment exposed the cells to black cohosh extract in methanol for 24 hours. These discrepancies, in 
addition to the unknown concentrations of the components within the supplements, need to be taken 
into account.  
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Figure 8: CellTiter 96 MTT Assay Reading of Black Cohosh Extract at 570nm 
 
MTT assay results for the grape seed extract had a similar pattern to β-estradiol, depicted below in 
Figure 9. The stock solution eluted a high proliferation rate and was read at 570nm, revealing an 
absorbance of 0.608. The reading remained close to baseline until cell proliferation began at one 
hundredth of the stock solution concentration. The high proliferation rates seen in this experiment 
oppose the conclusions drawn from the study of Chen et al. (Chen et al., 2009). The concentrations used 
in that study included increments from 40 to 200 mg/L and resulted in the inhibition of the proliferation 
of MCF-7 breast cancer cells. Their study suggested that grape seed extract had an overall 
antiproliferative effect. The results in this MTT assay are contradictory to those findings.  
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Figure 9: CellTiter 96 MTT Assay Reading of Grape Seed Extract at 570nm 
 
Red clover-induced proliferation remained close to the baseline throughout the assay, showing that 
there are no proliferative effects, as shown in Figure 10. Reiter et al. studied the effects of isoflavonoids 
such as genestein on cancer cells. They tested growth promotion, cell cycle arrest and apoptosis. Their 
findings suggested that the isoflavonoids from red clover inhibited cell proliferation. Although they 
cannot directly be compared due to the use of full red clover extract in this experiment rather than the 
isoflavonoids isolated from the red clover, the results from this MTT assay are consistent with the 
findings of Reiter et al. (Reiter et al., 2011). Similar to the other extracts, the concentration of the 
components of red clover were unknown causing difficulties when analyzing dose dependent effects.  
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Figure 10: CellTiter 96 MTT Assay Reading of Red Clover Extract at 570nm 
 
TACS MTT 
The TACS MTT assay was used to analyze the proliferative effects of each of the extracts and the peaks 
collected from them. These results are summarized below in Figures 11 through 16. The results using 
this assay were unreliable because neither the positive control of β-estradiol nor the negative control 
black cohosh were consistent with known results. For instance, the proliferation of cells treated with β-
estradiol using the TACS MTT assay showed an opposite trend to the work done by Wilson (Wilson et al., 
2004).   
Figure 11 below depicts the MTT assay results of the positive control β-estradiol in comparison to the 
blank. The linear trendline of the data shows that with increased concentration of β-estradiol, there was 
a decrease in proliferation. This pattern of proliferation does not coincide with what was expected. The 
research conducted by Wilson et al. showed an increase in proliferation when cells were treated with 
0.1 nM of β-estradiol. The results of this assay show that at 0.1 nM of β-estradiol, the cells had the 
lowest amount of proliferation, while the lowest concentration produced the highest proliferation.  
According to the findings of Wilson et al., as well as the findings from the CellTiter 96 MTT assay, the 
highest concentration of β-estradiol should contribute to the highest proliferation of T47D cells (Wilson 
et al., 2004).   
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Figure 11: TACS MTT Assay Reading of β-Estradiol Extract at 570nm 
 
As depicted in Figure 12, the black cohosh treated cells showed a slight increase in proliferation over the 
baseline growth. This increase in proliferation is not consistent with the findings of Al-Akoum et al. and 
Gaube et al. which both found black cohosh to cause antiproliferative effects (Al-Akoum et al., 2007; 
Gaube et al., 2007). However, in comparison to β-estradiol, the black cohosh proliferation rates were 
much lower shown by the slope of the linear trendline.   
 
  
Figure 12: TACS MTT Assay Reading of Black Cohosh Extract at 570nm 
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Through the conflicting results of black cohosh and β-estradiol, the validity of the TACS MTT assay was 
called into question. For this reason, the results of grape seed extract and red clover extract are graphed 
together in Figure 13 below. At higher concentrations, the grape seed extract shows high cell 
proliferation (0.06) when compared to the positive control (0.09). As the grape seed extract was diluted, 
its impact on cell growth decreased. The stock solution of red clover extract matched baseline 
proliferation levels. The proliferation rate increased at one hundredth of the stock concentration. The 
red clover extract resulted in greater proliferation than the positive control.  
 
 
Figure 13: TACS MTT Assay Reading of Red Clover and Grape Seed Extracts at 570nm 
 
The peak extracted from black cohosh stayed at baseline proliferation level until one tenth of the stock 
concentration, where proliferation increased. This is reflected in the positive slope of the trendline in 
Figure 14.  
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Figure 14: TACS MTT Assay Reading of Black Cohosh Peak at 570nm 
 
When compared to the full grape seed extract, the peak collected had reverse effects on cell growth. 
The trendline is negative in Figure 15, showing a decrease in proliferation as concentration increased. 
The lowest concentration of the grape seed extract peak resulted in the highest reading (0.24) of any 
other tested in this experiment.  
 
 
Figure 15: TACS MTT Assay Reading of Grape Seed Peak at 570nm 
 
 34 
Figure 16 shows all four red clover extracted peaks for comparative analysis. Peak 1, peak 3, and peak 4 
all show a decreasing proliferation with increasing concentration. Peak 2 does not have a prominent 
effect on cell growth when compared to the others in this experiment. Both peak 1 and peak 3 have 
similar trends of growth comparative to the complete red clover extract, having the highest proliferation 
at the lowest concentration.  
 
 
 
Figure 16: TACS MTT Assay Reading of Red Clover Peaks at 570nm 
 
The slope of each linear trendline and the range for each extract for the TACS MTT assay are recorded 
below in Table 5. Black cohosh extract has the smallest range and lowest absolute value of the slopes 
recorded. As the positive control, β-estradiol has the second lowest range and slope. Grape seed extract 
is the only supplement that resulted in a positive slope. The largest range in proliferation readings was 
seen in red clover with a range of 0.158. Together, the data summarized in Table 5 are inconsistent and 
generally uninterpretable. 
 
Sample Slope  Range 
β-estradiol   -0.0109 0.0409 
Black Cohosh extract -0.0015 0.0070 
Grape Seed extract 0.0286 0.0800 
Red clover extract  -0.0604 0.1580 
Table 5: T47D-KBluc Breast Cancer Cell Proliferation Trends in Various Phytoestrogens 
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Conclusions 
 
Based on analysis of the HPLC and MTT assay results, the following conclusions were drawn regarding 
the black cohosh, red clover, and grape seed supplements.  
Through HPLC, the most prominent components of the extracts were observed and isolated.  
The HPLC data showed only minor correlation between phytoestrogen standards tested and red clover 
and grape seed extracts. Thus, the identities of the compounds included in these dietary supplements 
remain largely unknown. Although the most prominent peaks were collected, they may not be 
phytoestrogens or have notable effects on cell proliferation. Additionally, the compounds depicted in 
the HPLC data may not independently impact breast cancer cell growth, but collectively could have 
agonistic or antagonistic effects. As previously mentioned, the study performed by Al-Akoum et al. 
provided evidence of antagonistic effects of tamoxifen, blocking the estrogen receptor (Al-Akoum et al., 
2007). When cells were treated with tamoxifen and β-estradiol together, tamoxifen prevented the 
proliferative effects previously seen with β-estradiol by binding the ERα. Similarly, the various 
components in the supplements could counteract each other. For example, Ji et al. isolated the 
phytoestrogen formononetin from black cohosh and applied only the purified sample to the cells. This 
experiment demonstrates that formononetin causes estrogenic effects within the cell (Ji et al., 2005). 
Alternatively, Gaube et al. and Al-Akoum et al. show that black cohosh as a whole has no effect on 
proliferation of breast cancer cells (Gaube et al., 2007; Al-Akoum et al., 2007). This discrepancy may be 
explained by the various agonistic and antagonistic components within black cohosh along with any of 
the other supplements used in this study. Therefore, it is important to identify the variety and level of 
individual phytoestrogens in each supplement. 
In addition to the effects of varying supplement components, the ratios of each component within the 
pill can differ. According to Albulescu et al., daidzein and genistein could be isolated from red clover 
extract but in this HPLC, neither was present (Albulescu et al., 2006). These differences can be due to 
plant growth conditions or varying harvest and preparation protocols. The metabolic production can be 
effected by these inconsistencies. This can pose a health threat for women ingesting the supplements if 
the levels of estrogenic components fluctuate among batches of the same supplement.   
The results of the CellTiter 96 MTT assay were more consistent with recently published literature than 
the TACS MTT assay. The increase in proliferation of the breast cancer cells treated with the positive 
control β-estradiol confirmed this conclusion. In comparison, the cells treated with β-estradiol stock 
solution did not show any proliferation when using the TACS MTT assay; thus, this assay was considered 
unreliable. Therefore, the main conclusions were drawn from the CellTiter 96 MTT assay.  
The growth of black cohosh treated cells resembled that of untreated cells. Additionally, compared to 
the growth of β-estradiol there was little proliferation. Therefore, this supplement properly served as 
the negative control chosen based on the work of Gaube et al. and Al-Akoum et al. (Gaube et al., 2007; 
Al-Akoum et al., 2007).  Overall, black cohosh stock solution did not appear to have an effect on the 
breast cancer cells. According to Reiter et al., red clover should have had antiproliferative effects on the 
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breast cancer cell growth. However, this was not possible to replicate due to the unknown 
concentrations of components in the extracted supplements. The cells treated with red clover in this 
study showed slight variance in cell growth from untreated cells. Similar to black cohosh, these treated 
cells resulted in very little proliferation compared to β-estradiol. Testing revealed that cells treated with 
grape seed caused cell proliferation similar to β-estradiol. The stock solution of grape seed caused a 
higher amount of cell growth than both red clover and black cohosh. This opposes the findings of Chen 
et al. which found grape seed to cause antiproliferative effects on the breast cancer cell line. However, 
further studies should be done in order to conclusively determine that grape seed extract had 
proliferative effects similar to that of β-estradiol.   
In the future, the HPLC data should be looked at more closely. The extracts should be run through a 
different column at a slower elution rate to allow better extraction of peaks. Using mass spectrometry, 
the specific characteristics of each peak could be analyzed and compared to known compounds. This 
could help identify certain peaks. Additionally, HPLC can be used to compare the components of 
supplements from different manufacturers as well as the composition of supplements from the same 
bottle in order to observe variation from pill to pill.   
To definitively observe the effects of treating breast cancer cells with the extracts, immunoblots can be 
used instead of MTT assays. Proliferating cell nuclear antigen (PCNA) is a protein that indicates the 
synthesis of DNA and therefore cell proliferation. Caspase-3 is an enzyme in the apoptotic cascade 
showing cell death. Through the use of these proteins, immunoblots would reveal cell production of 
proliferative or apoptotic cell signals.  
In addition to viewing the effects of immunoblots, the extracts should be applied to breast cancer cells 
for various time periods. According to Howell and Cuzick, MCF-7 breast cancer cells experienced 
different effects depending on the duration of estrogen exposure. When estrogen levels declined, 
tumors adapted to the growth at the new level, but when estrogen was reintroduced, the cell growth 
was inhibited (Howell & Cuzick, 2012). These experiments could indicate that estrogen receptor binding 
may fluctuate with exposure time.  
In order to accurately determine how these phytoestrogens will react in a biological organism, further 
experiments should be conducted to see which receptors are activated and how the supplements are 
absorbed into the cell.  First, it should be confirmed that phytoestrogens enter the cells through the 
same receptor as β-estradiol. Additionally, it would be beneficial to have a thorough study of 
phytoestrogens’ effects on DNA replication once it enters the cell.  
Due to loose regulation of dietary supplements, products with questionable contents are made available 
and falsely advertised. Since the compounds in the supplements have not been identified, these 
products need regulation and should not be sold as dietary supplements until further studies are 
conducted. Proof of safety and efficacy should be provided prior to advertisement of these products as a 
safe alternative to hormone replacement therapy.  
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